Debt-laden Takeda to sell OTC drugs in Middle East and Afric...

Takeda is to sell off a portfolio of over-the-counter and prescription drugs in the Near East, Middle East, and Africa for $200 million to Acino, as the Japanese company aims to pay off bil

Takeda breaks into top 20 largest pharmas with Shire merger

Takeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger with Shire earlier this year, according to a new analysis using market capitali

Sobi stays on its acquisitive streak with $915m Dova deal

Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova

Takeda eyes emerging markets asset sale to trim its debt; re...

Lundbeck to acquire Alder, and migraine drug, for $1.95bn

Lundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.

Unions call on US antitrust regulators to block $63 billion ...

US antitrust authorities are coming under pressure from consumer groups and unions to block the proposed $63 billion merger of AbbVie and Allergan, according to a press report.